Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference
Event summary
- Oragenics will present at Sidoti’s Micro-Cap Virtual Investor Conference on May 21, 2026, at 3:15 ET.
- The company will also host virtual one-on-one meetings with investors on May 20-21, 2026.
- Oragenics is a clinical-stage biopharmaceutical company focused on neurological therapeutics.
- The company’s lead candidate, ONP-002, is in Phase IIa clinical trials for concussion and mild traumatic brain injury.
- Sidoti Events is a leading provider of corporate access for small and microcap companies.
The big picture
Oragenics’ participation in Sidoti’s Micro-Cap Virtual Investor Conference underscores its strategic focus on engaging with institutional investors to support its clinical-stage development. The event provides a platform for the company to showcase its proprietary intranasal delivery technology and progress in neurological therapeutics, particularly in the treatment of concussion and mild traumatic brain injury. Sidoti’s strong ties to small and microcap investors could amplify Oragenics’ reach within the sector.
What we're watching
- Clinical Progress
- The pace at which Oragenics advances ONP-002 through Phase IIa trials in Australia and plans for U.S. Phase IIb trials.
- Investor Sentiment
- How the company’s presentation and one-on-one meetings impact investor confidence and potential funding opportunities.
- Market Positioning
- Whether Oragenics can leverage Sidoti’s extensive network to enhance its visibility among institutional investors.
Related topics